Table 1.
Mean dose, dose limits for planning target volumes (PTV) and dose constraints for organs at risk (OAR)
| Target/OAR | Mean Dose | Dmax | Dose volume limits |
|---|---|---|---|
| PTVPET | 79.7 Gy | - | - |
| PTVgross-PET | 73.1 Gy (± 1 Gy) | - | - |
| PTV1-gross | 69.7 Gy (± 1 Gy) | - | - |
| PTV2–1 | 60 Gy (± 1 Gy) | - | - |
| PTV3–2 | 52.8 Gy (± 1 Gy) | - | - |
| PTV1 | - | - | D98%> 64.6 Gy |
| PTV3 | - | - | D98%> 46 Gy |
| Spinal cord | - | 45 Gy | - |
| Brain stem | - | 54 Gy | - |
| Mandible | - | 70 Gy (72.5 can be accepted in certain circumstances) | - |
| Anterior eye | - | 30 Gy | - |
| Chiasm and optic nerves | - | 54 Gy | - |
| Inner ear | - | - | Dmean ≤ 45 Gy, D95%≤45 Gy |
| Parotid gland | - | - | Dmean≤26 Gy (ipsilateral) ≤20 (contralateral) |
| Larynx | - | - | V50Gy≤ 33% |
| Submandibular glands | - | - | Dmean≤35 Gy; only if level I and II is not in the target |
PTVPET = GTVPET with a 4 mm margin; PTVgross = GTV with a 4 mm margin (GTV = macroscopic tumor in T and N position defined from clinical evaluation and CT); PTV1 = CTV1 with a 4 mm margin (CTV1 = GTV with a 1 cm margin); PTV2 = CTV2 with a 4 mm margin (CTV2 = CTV1 and volume with a high risk of subclinical tumor spread) ; PTV3 = CTV3 with a 4 mm margin (CTV3 = CTV2 and elective lymph node levels without a margin, elective lymph node levels depends on tumor sub-site, T and N stage).